Skip to main content
SpringerLink
Log in

Which is the Best Chemotherapeutic Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma?

  • Letter to the Editor
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pascale F, Bedouet L, Baylatry M, Namur J, Laurent A. Comparative chemosensitivity of VX2 and HCC cell lines to drugs used in TACE. Anticancer Res. 2015;35(12):6497–504.

    PubMed  Google Scholar 

  2. Boulin M, Guiu S, Chauffert B, et al. Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma. Anticancer Drugs. 2011;22(8):741–8.

    Article  CAS  PubMed  Google Scholar 

  3. Favelier S, Boulin M, Hamza S, et al. Lipiodol trans-arterial chemoembolisation of hepatocellular carcinoma with idarubicin: first experience. Cardiovasc Intervent Radiol. 2013;36(4):1039–46.

    Article  PubMed  Google Scholar 

  4. Boulin M, Hillon P, Cercueil JP, et al. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther. 2014;39(11):1301–13.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, University Hospital, Dijon, France

    Mathieu Boulin

  2. Department of Radiology, Saint-Eloi University Hospital, Montpellier, France

    Boris Guiu

  3. Department of Interventional Radiology, Saint-Eloi University Hospital, 80 Avenue Augustin Fliche, 34295, Montpellier, France

    Boris Guiu

Authors
  1. Mathieu Boulin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Boris Guiu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Boris Guiu.

Ethics declarations

Conflict of interest

None of the authors have any conflicts of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boulin, M., Guiu, B. Which is the Best Chemotherapeutic Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma?. Cardiovasc Intervent Radiol 39, 953–954 (2016). https://doi.org/10.1007/s00270-016-1319-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-016-1319-0

Keywords

Search

Navigation